Lanicemine dihydrochloride
CAS: 153322-06-6
Ref. 3D-DGA32206
5mg | Ausgelaufen | ||
10mg | Ausgelaufen | ||
25mg | Ausgelaufen | ||
50mg | Ausgelaufen | ||
100mg | Ausgelaufen |
Produktinformation
- (1S)-1-Phenyl-2-(pyridin-2-yl)ethan-1-amine dihydrochloride
- (S)-α-Phenyl-2-pyridineethanamine dihydrochloride
- 2-Pyridineethanamine, α-phenyl-, dihydrochloride, (S)-
- 2-Pyridineethanamine, α-phenyl-, dihydrochloride, (αS)-
- 2-Pyridineethanamine, α-phenyl-, hydrochloride (1:2), (αS)-
- AZD-6765 dihydrochloride
- Ar-R 15896Ar
- Ar-R15896Ar
- Arl 15896Ar
- Arl-15896
- Mehr Synonyme anzeigen
- FPL-15035AR(racemate)
- FPL-15895AR((-)-enantiomer)
- FPL-15896AR(former code)
- Fpl 15896Ar
- Lanicemine hydrochloride
Lanicemine dihydrochloride is an analog of a Chinese medicinal compound that has been found to have anticancer properties. It works by inhibiting kinases, which are enzymes that play a key role in the growth and spread of cancer cells. Lanicemine dihydrochloride has been shown to induce apoptosis, or programmed cell death, in cancer cells. This drug is also being studied as a potential inhibitor of protein-protein interactions involved in tumor formation and progression. Lanicemine dihydrochloride has been detected in urine following administration, suggesting that it may be suitable for use as a urinary biomarker for monitoring treatment efficacy. Overall, this drug shows promising potential as an effective anticancer agent with unique mechanisms of action.